Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.55 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.52 |
| ▸ | IDO1 | P14902 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29487720 | 0.98 | PNMT (0.54) | PNMTNPC1RAB9ACHRM2TAAR1 | |
| Hydrochloric Acid SCHEMBL18300833 | 0.98 | PNMT (0.54) | PNMTNPC1RAB9ACHRM2TAAR1 | |
| SCHEMBL8224664 | 0.82 | PNMT (0.61) | PNMTTAAR1IDO1CYP3A4CYP2D6 | |
| SCHEMBL6072254 | 0.80 | CHRM2 (0.72) | PNMTNPC1RAB9ACHRM2TAAR1 | |
| SCHEMBL8225435 | 0.79 | PNMT (0.42) | PNMTTAAR1IDO1MEN1KMT2A | |
| SCHEMBL6869146 | 0.78 | IDO1 (0.58) | PNMTNPC1RAB9ACHRM2TAAR1 | |
| Iodide SCHEMBL9478324 | 0.78 | CHRM2 (0.69) | PNMTNPC1RAB9ACHRM2TAAR1 | |
| SCHEMBL21369337 | 0.77 | TAAR1 (0.64) | PNMTNPC1RAB9ACHRM2TAAR1 | |
| SCHEMBL2828642 | 0.77 | KCNJ5 (0.56) | NPC1RAB9AMEN1KMT2ACYP3A4 | |
| Hydrochloric Acid SCHEMBL15066404 | 0.77 | HTT (0.44) | PNMTTAAR1IDO1CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106700130-B | A kind of composite modified melamine cyanurate flame retardant and its preparation method and application | 湖州利鹏新材料科技有限公司 | 2019-06-21 | — | — | CN | claimed |
| CN-106700130-A | Composite modified melamine cyanurate fire retardant and preparation method and application of fire retardant | 湖州利鹏新材料科技有限公司 | 2017-05-24 | — | — | CN | claimed |
| US-20250257039-A1 | MCT4 INHIBITORS FOR TREATING DISEASE | Vettore, LLC | 2025-08-14 | — | — | US | disclosed |
| US-12187682-B2 | MCT4 inhibitors for treating disease | Vettore, LLC (US) | 2025-01-07 | — | — | US | disclosed |
| US-20240294523-A1 | HETEROCYCLIC LACTAM COMPOUND, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2024-09-05 | — | — | US | disclosed |
| US-20240101518-A1 | MCT4 INHIBITORS FOR TREATING DISEASE | Vettore, LLC | 2024-03-28 | — | — | US | disclosed |
| CN-117460731-A | Heterocyclic lactams, process for their preparation and their use in medicine | 劲方医药科技(上海)有限公司 | 2024-01-26 | — | — | CN | disclosed |
| US-11724989-B2 | MCT4 inhibitors for treating disease | Vettore, LLC (US) | 2023-08-15 | — | — | US | disclosed |
| WO-2022258052-A1 | HETEROCYCLIC LACTAM COMPOUND, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | 劲方医药科技(上海)有限公司 | 2022-12-15 | — | — | WO | disclosed |
| WO-2022258052-A1 | HETEROCYCLIC LACTAM COMPOUND, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | 劲方医药科技(上海)有限公司 | 2022-12-15 | — | — | WO | disclosed |
| CN-114956933-A | Marker containing isotope oxygen atom and preparation method and application thereof | 清华大学 | 2022-08-30 | — | — | CN | disclosed |
| EP-1272456-B1 | HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS | ABBOTT LAB (US) | 2004-10-27 | — | — | EP | disclosed |
| US-20040167126-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | ABBVIE INC. | 2004-08-26 | — | — | US | disclosed |
| WO-2003097063-A1 | DERIVATIVES OF 2-(1-BENZYL-1H-PYRAZOLO (3, 4-B)PYRIDINE-3YL) -5-(4-PYRIDINYL)-4-PYRIMIDINE AMINE AND THE USE THEREOF AS GUANYLATE CYCLASE STIMULATORS | BAYER HEALTHCARE AG (DE) | 2003-11-27 | — | — | WO | disclosed |
| EP-1272456-A1 | HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS | Abbott Laboratories (US) | 2003-01-08 | — | — | EP | disclosed |
| US-20020002152-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | ABBOTT LABORATORIES | 2002-01-03 | — | — | US | disclosed |
| WO-2001079157-A1 | HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS | ABBOTT LABORATORIES (US) | 2001-10-25 | — | — | WO | disclosed |
| US-4076943-A | DIURETICS, SALURETICS, ANTIHYPERTENSIVES | BAYER AKTIENGESELLSCHAFT (DT) | 1978-02-28 | — | — | US | disclosed |
| US-4061653-A | DIURETIC, SALURETIC, ANTIHYPERTENSIVE | BAYER AKTIENGESELLSCHAFT (DT) | 1977-12-06 | — | — | US | disclosed |
| US-3950528-A | HYPOTENSIVE AGENTS, SALURETICS, DIURETICS | BAYER AKTIENGESELLSCHAFT (DT) | 1976-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12187682-B2 | MCT4 inhibitors for treating disease | SLC16A1, SLC16A3, SLC16A7 | PNMT 2688/4885NPC1 141/4885RAB9A 2999/4885 |
| US-20250257039-A1 | MCT4 INHIBITORS FOR TREATING DISEASE | SLC16A1, SLC16A3, SLC16A7 | PNMT 2688/4885NPC1 141/4885RAB9A 2999/4885 |
| US-20240294523-A1 | HETEROCYCLIC LACTAM COMPOUND, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | RIPK1, RIPK4, RIPK3 | PNMT 4877/4885NPC1 1614/4885RAB9A 983/4885 |
| US-20240101518-A1 | MCT4 INHIBITORS FOR TREATING DISEASE | SLC16A1, SLC16A3, SLC16A8 | PNMT 2023/4885NPC1 148/4885RAB9A 3054/4885 |
| US-20040167126-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | METAP2, METAP1, ANPEP | PNMT 919/4885NPC1 3808/4885RAB9A 2314/4885 |
| US-11724989-B2 | MCT4 inhibitors for treating disease | SLC16A1, SLC16A3, SLC16A7 | PNMT 2688/4885NPC1 141/4885RAB9A 2999/4885 |
| US-20020002152-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | METAP2, METAP1, ANPEP | PNMT 919/4885NPC1 3808/4885RAB9A 2314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.